
BET inhibitors combined with JAK inhibitors well-tolerated with myelofibrosis
The BET inhibitor BMS986158 has shown promising preliminary data of potential disease modification in patients with intermediate- or high-risk myelofibrosis when used in combination with ruxolitinib and fedratinib. The phase 1/phase 2 CA011-023 study, led by Dr. Haifa Kathrin Al-Ali, head of the Krukenberg Cancer Center at University Hospital of Halle in Germany, examined 16…